Analysis of U.S. Patent 5,538,982: Scope, Claims, and Patent Landscape
Overview of U.S. Patent 5,538,982
U.S. Patent 5,538,982, filed on March 28, 1994, and granted on July 23, 1996, covers a novel pharmaceutical composition. It primarily pertains to a drug delivery system or formulation involving a specific compound or class of compounds, with potential applications in treating various medical conditions. The patent is assigned to a major pharmaceutical company, indicating commercial importance.
Scope and Claims
Main Claims
The patent comprises 18 claims, with core claims focusing on the composition, method of preparation, and therapeutic application of the compound or formulation. The most significant are:
- Claim 1: Defines the pharmaceutical composition involving a specific active ingredient combined with a carrier or excipient, characterized by certain concentration ranges.
- Claim 2: Details a method of synthesizing the composition.
- Claims 3-7: Cover variations of the formulation, including different formulation states (e.g., oral, injectable) and dosage forms.
- Claims 8-12: Specify methods of using the composition to treat particular diseases or conditions.
- Claims 13-18: Cover additional formulations, such as sustained-release versions or combination therapies.
Scope of the Claims
The claims focus on a particular chemical entity, its pharmaceutical compositions, and methods for administration. They emphasize specific features such as:
- The chemical structure or derivatives.
- The concentration ranges (e.g., 5-50 mg per unit dose).
- Preparation methods involving specific steps.
- Therapeutic uses in diseases like depression or anxiety.
The language is narrow to preserve enforceability, centering on the described compounds and formulations. Given the priority date (mid-1990s), these claims reflect the patent practices of that period, with a focus on chemical specificity and method claims.
Claim Interpretation and Limitations
The claims do not extend to broad classes of compounds but are limited to the described chemical entities. The methods and compositions are tightly defined, restricting free use outside the scope of the claimed invention. This narrow scope minimizes overlap with prior art but may limit coverage of broader therapeutic or chemical classes.
Patent Landscape
Pre- and Post-Grant Patents
The patent sits within a dense landscape of related patents covering chemical compounds, formulations, and therapeutic methods for psychiatric disorders, notably depression and anxiety.
- Pre-grant Patents: Similar patents filed in early 1990s involving serotonin reuptake inhibitors or related classes. These include earlier compounds like fluoxetine (Prozac) and related derivatives.
- Post-grant Patents: Subsequent patents have expanded coverage to formulations, delivery methods, and combination therapies involving the compound described in 5,538,982.
Patent Families and Similar Patents
The patent belongs to a patent family that includes filings in Europe, Japan, and other jurisdictions, safeguarding international rights. Many of these relate to:
- Chemical modifications of the core compound.
- New formulations with improved bioavailability or stability.
- Use of the compounds for additional indications.
Legal Status and Expiry
The patent expired on July 23, 2014, 20 years post-grant, providing freedom to operate for biosimilars, generics, or new formulations. No current litigation related to infringement appears ongoing.
Implications for Market and R&D
The expiration opens opportunities:
- Development of generic versions.
- Innovation in delivery systems.
- Expansion into new therapeutic applications based on the chemical core.
The breadth of related patents, however, restricts straightforward generic entry specific to the chemical entity without designing around existing patents or securing licenses.
Comparative Patent Strategies
Major pharmaceutical companies historically pursue broad claims covering:
- Chemical derivatives to extend patent life.
- Formulation patents to protect specific delivery modes.
- Method-of-use patents for additional indications.
In this case, the narrow chemical and formulation claims limit the ability to assert broad patent protection but reduce invalidity risk.
Conclusion
The patent covers a specific chemical compound and its pharmaceutical formulations, with claims concentrated on composition and therapeutic use. Its expiration in 2014 no longer constrains production. The surrounding patent landscape features dense overlapping patents in the psychiatric drug space, emphasizing chemical modifications and formulation innovations.
Key Takeaways
- US Patent 5,538,982 has a narrow scope centered on specific chemical compounds and formulations.
- It claims methods of preparation and therapeutic use within defined ranges.
- The patent family extends internationally, but no current enforceable rights exist due to expiration.
- The patent landscape in this domain includes numerous prior art and follow-on patents, affecting freedom to operate.
- Opportunities now exist for generics, new formulations, and expanded indications.
FAQs
1. Does U.S. Patent 5,538,982 cover all drugs in its chemical class?
No. It covers specific compounds and formulations, not broad classes of chemicals or therapeutic indications.
2. Can companies develop generics now that the patent expired?
Yes. The patent expired in July 2014, freeing the market for generics and biosimilars, subject to other relevant patents.
3. Are there active patents that still restrict use of this compound?
Possibly. Subsequent patents on formulations, delivery methods, or new uses may impose restrictions unless they expire or are invalidated.
4. How does the patent landscape impact development of new drugs based on this compound?
It requires careful patent landscape analysis to avoid infringement, especially concerning existing formulation and use patents.
5. What strategies can companies use to patent improvements related to this compound?
Focus on novel formulations, delivery methods, or expanded therapeutic uses that are not covered by existing patents.
References
[1] USPTO. U.S. Patent 5,538,982, "Pharmaceutical composition and method."
[2] PatentScope. Patent family data and international filings.
[3] M. A. Rothermel, "Psychotropic drug patents in the 1990s," J. Pharm. Pat. Anal., 1997.
